RMR Wealth Builders Buys 416 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

RMR Wealth Builders boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 10.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,492 shares of the medical equipment provider’s stock after purchasing an additional 416 shares during the quarter. RMR Wealth Builders’ holdings in Intuitive Surgical were worth $1,515,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new position in shares of Intuitive Surgical in the 3rd quarter valued at $25,000. Baystate Wealth Management LLC raised its stake in shares of Intuitive Surgical by 150.0% in the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 45 shares during the last quarter. MCF Advisors LLC raised its stake in shares of Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 40 shares during the last quarter. Headinvest LLC acquired a new stake in shares of Intuitive Surgical during the third quarter worth about $28,000. Finally, Stone House Investment Management LLC increased its holdings in Intuitive Surgical by 100.0% in the 3rd quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 50 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on ISRG shares. Barclays lifted their price objective on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a research note on Thursday, January 25th. Stifel Nicolaus increased their price target on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Raymond James boosted their price objective on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a report on Thursday, January 25th. Truist Financial raised their target price on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Finally, StockNews.com downgraded Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

Insider Buying and Selling at Intuitive Surgical

In related news, EVP Myriam Curet sold 481 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $386.09, for a total value of $185,709.29. Following the sale, the executive vice president now owns 298 shares in the company, valued at approximately $115,054.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Mark J. Rubash sold 1,709 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $380.00, for a total transaction of $649,420.00. Following the sale, the director now directly owns 16,051 shares in the company, valued at $6,099,380. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Myriam Curet sold 481 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $386.09, for a total transaction of $185,709.29. Following the transaction, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $115,054.82. The disclosure for this sale can be found here. Insiders have sold a total of 147,927 shares of company stock valued at $57,064,459 over the last quarter. 0.80% of the stock is owned by company insiders.

Intuitive Surgical Price Performance

Shares of ISRG stock opened at $380.37 on Thursday. The firm’s 50-day moving average is $385.34 and its two-hundred day moving average is $351.97. The company has a market capitalization of $134.92 billion, a PE ratio of 68.66, a price-to-earnings-growth ratio of 4.93 and a beta of 1.39. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.00 earnings per share. Sell-side analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.